Ghana has granted full national licensure for the University of Oxford’s R21/Matrix-M malaria vaccine, marking the first regulatory clearance for the vaccine for use in any country. Developed by the University of Oxford, leveraging Novavax’s adjuvant technology, and manufactured and scaled up by the Serum Institute of India PvT Ltd (SIIPL), the vaccine has been […]
Hope that malaria could be eradicated forever has been given a boost after new findings from a vaccine trial showed a high-rate of efficacy. Researchers from the University of Oxford and their partners have yesterday (September 8) reported new findings from their malaria vaccine R21/Matrix-M phase 2b trials following the administration of a booster dose. […]
Oxford Science Enterprises (OSE), the independent investment company created to found, fund and build transformational businesses via its partnership with the University of Oxford, has raised a further £250 million ($300 million) in funding. This brings the total amount raised by OSE to more than £850 million ($1 billion) since inception in 2015. These funds […]
As AstraZeneca and the University of Oxford’s Covid-19 vaccine debuts in the EU market this month, supply bottlenecks, viral variants, and political squabbles demonstrate that the quest to develop and distribute Covid-19 vaccines is far from over. The list of approved Covid-19 vaccines in Europe is growing ever longer with the EMA approval of the […]
A much anticipated Covid-19 vaccine, developed by the University of Oxford and AstraZeneca, achieved 70% efficacy in phase III interim data. While less effective on paper, it could prove cheaper and easier to distribute than its most advanced competitors. Scientists and politicians heartily received the announcement of promising interim clinical trial results from the Covid-19 […]
MiroBio has spun out of the University of Oxford with a Series A round of €30M (£27M) to develop treatments for autoimmune diseases that don’t disrupt the immune system as a whole. The big Series A round accompanying MiroBio’s launch was co-led by the university’s investor partner Oxford Sciences Innovation and the US investor Samsara […]
CN Bio Innovations has globally launched an organ-on-a-chip device that allows scientists to test potential drugs on living human organ models. CN Bio Innovations, an Oxford University spin-out, has launched a device that enables scientists to test potential drugs in conventional cell culture labs without the need for animal models. The technology, which has been […]
NightstaRx has raised €39.5M that will go towards three clinical programs testing gene therapies for rare diseases that cause blindness. NightstaRx is developing gene therapies for genetic retinal diseases that cause blindness, with technology from the University of Oxford. Now getting closer to the market, the company has closed a Series C round with $45M (€39.5M) […]
Evotec and the University of Oxford have announced the academic projects that will receive a financial award to push them towards launching spin-outs. LAB282 is a partnership between the German biotech Evotec, Oxford University Innovation and Oxford Sciences Innovation, the University’s venture fund manager. Set up with the aim to bridge academia and industry in life sciences, LAB282 […]
Scenic Biotech is applying a technology to identify first-in-class therapeutic targets that has secured it €6.5M in Series A. Scenic Biotech, founded in Amsterdam just this year, has raised €6.5M to exploit the potential of a technology to discover new types of disease-related genes with applications in cancer and rare genetic diseases. The company, created in […]
Mission Therapeutics has received a grant to support the development of a novel approach to treating Parkinson’s that is attracting top partners worldwide. Right on time for World Parkinson’s Day today, Mission Therapeutics has announced it has been awarded a research grant from the Michael J. Fox Foundation in the US. Named after its founder, the star of […]